CASE REPORT WITH REVIEW OF LITERATURE
December 4, 2024
CASE REPORT WITH REVIEW OF LITERATURE
November 30, 2024
CASE REPORT WITH REVIEW OF LITERATURE
November 21, 2024
STATE-OF-THE-ART REVIEW IN ENDOCRINOLOGY
November 12, 2024
STATE-OF-THE-ART REVIEW IN ENDOCRINOLOGY
October 10, 2024
CASE REPORT WITH REVIEW OF LITERATURE
September 25, 2024
STATE-OF-THE-ART REVIEW IN ENDOCRINOLOGY
September 5, 2024
ORIGINAL
Featured Article Vol 71 Issue 12 (December, 2024)
REVIEW
Vol 71 Issue 12 (December, 2024)
ORIGINAL
Vol 71 Issue 12 (December, 2024)
ORIGINAL
Vol 71 Issue 12 (December, 2024)
CASE REPORT WITH REVIEW OF LITERATURE
Vol 71 Issue 12 (December, 2024)
Recommendation from the Editor in Chief
Ethnicity-dependent differences in drug responsiveness have attracted broad attention also in endocrinological science. In this issue, Dr. Akira Shimatsu and Professor Beverly MK Biller at Massachusetts General Hospital, an active member of international honorary editors of Endocrine Journal, contribute an insightful original article focusing on ethnicity-related impact of oral 11beta-hydroxylase inhibitor, Osilodrostat between patients with Cushing’s disease of Asian and non-Asian origin. In comparison with non-Asians, Asian patients required apparently-lower doses of the drug to achieve clinical benefits, whereas adverse events related with hypocortisolism were manifested in Asians. As authors stated, this study is the first to compare the impact of drug therapy for patients with Cushing’s disease between Asian and non-Asian origin. Although ethnicity-dependent differences in bioavailability of the drug would be involved, elucidation of the entire picture is strongly anticipated.